Our mission?
To improve patients’ lives
Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care.
Our passion drives our commitment to patients living with difficult-to-treat diseases, and we put them first. Because patients are our priority, we help them through our expertise in oncology, neuroscience, and rare disease.
We bring medicines to patients with the strength of nearly 6,000 employees across the globe, including innovators in our key therapeutic areas.
Download our annual reportAbout
Oncology
Our oncology work focuses on solid tumors and some of the hardest-to-treat cancers. We power a growing portfolio of therapies aimed at improving the lives of patients with gastrointestinal and pancreatic neuroendocrine tumors, carcinoid syndrome, and pancreatic cancer.
Neuroscience
People suffering from neurological disorders are in need of treatments, and we’ve become a global leader in creating them through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older, and cervical dystonia in adults.
Rare disease
We continue to evolve and grow our research efforts in the area of rare and ultra-rare disease. Given the limited understanding of these diseases, we are committed to addressing patient needs, from supporting diagnosis to treatment with specific investment in pituitary pathologies, growth disorders, and ultra-rare bone diseases, including fibrodysplasia ossificans progressiva, commonly known as FOP.
Clinical Trials
Clinical trials can lead to medical outcomes that help improve lives, and we thank all of our patients who make this critical research possible through their participation in trials. If you would like to learn more about enrolling in a study, visit clinicaltrials.gov.
Responsibility is our policy
Company Responsibility
As part of our virtual Week of Service, our colleagues across the U.S. are giving back to their local communities in a safe, socially-distanced way. A huge thanks to all of our participants and our partners, @LS_Cares and @TheHopeFactory, for helping those in need. #WeAreIpsen
— IpsenUS (@IpsenUS) November 16, 2020
As a company, we put patients at the center of everything we do by working in collaboration with, and for, patients. At this year's @IFOPA Virtual Family Gathering and throughout the year, we are inspired by the resilience, strength and positivity of the FOP community.
— IpsenUS (@IpsenUS) November 23, 2020
Meet our leadership team
Richard Paulson
Chief Executive Officer, Ipsen North America
Shahrzad Amirani
Vice President, Head of New Products & Innovation
Kimberly Baldwin
Vice President, Value & Access
Jennifer Benenson
Senior Vice President and North America General Counsel, Legal Affairs
Stephanie Brown
Senior Vice President and Business Unit Head, Rare Disease – North America
Lisa DiPaolo
Senior Vice President, Human Resources, North America, Global R&D, Business Development & Talent Acquisition
Ed Dybka
General Manager, Ipsen Canada
Karla MacDonald
Vice President, Communications and Patient Advocacy
Eduardo Obraczka
Vice President, Business Operations & Chief of Staff, North America
Awny Farajallah
Senior Vice President, North America Medical Affairs
Drew Sansone
Vice President, Regulatory Affairs, Quality & Safety, North America
Elliot Beimel
Vice President, Finance, North America
Giota Papamarkou
Vice President, Business Ethics North America & Global Monitoring
Chris Watters
Vice President, Franchise Head, Neuroscience Business Unit
Leadership